Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032

Key Highlights:

• As per DelveInsight's analysis, the total incident cases of NSCLC in the 7MM were approximately 527,000 cases in 2022; these cases are estimated to increase by 2032.
• Among EU4 countries, Germany accounted for the highest number of NSCLC cases in 2019, whereas Spain accounted for the lowest cases in 2019.
• NSCLC is diagnosed at an advanced stage in nearly 50% of patients. Increased screening and detection have resulted in a concomitant rise in the incidence of Stage I NSCLC and a decline in Stage IV NSCLC.
• Various types of mutations are commonly observed in NSCLC. There is mounting evidence that substantial molecular and clinical heterogeneity exists within oncogenic driver-defined subgroups of NSCLC. The most frequent biomarkers are EGFR in Japan and KRAS in the US and Europe.
• EGFR exon 19 deletions and Exon 21 L858R substitution (sensitizing mutations) account for approximately 80% of EGFR mutations in NSCLC.
• The total incident cases of EGFR Non-small Cell Lung Cancer in the US was ~30,000 in 2022.
• The most frequent KRAS variant observed in NSCLC is G12C. In the United States, KRASG12C is present in ~37% of NSCLC cases.
• In 2022, the total incident cases of NTRK metastatic Non-small Cell Lung Cancer in the 7MM was around 1,100.

DelveInsight's "Metastatic Non-small Cell Lung Cancer - Epidemiology - 2032" report delivers an in-depth understanding of metastatic non-small cell lung cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Metastatic Non-small Cell Lung Cancer Disease Understanding

Metastatic Non-small Cell Lung Cancer Overview and Diagnosis

Non-small Cell Lung Cancer is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. Early diagnosis offers the best prognosis for Non-Small Cell Lung Cancer. However, Non-Small Cell Lung Cancer and other lung cancers can be difficult to diagnose because these cancers often have symptoms mistaken for common illnesses or the effects of long-term smoking. Because of this, 80% of people diagnosed with Non-Small Cell Lung Cancer have already progressed to advanced stages, making it more difficult to treat. If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around the lungs. The physician may also examine a sample of mucus under the microscope.

If these initial tests identify cancer, a lung biopsy can be conducted. A bronchoscopy can also be recommended, allowing the physician to visualize and remove tissue. If lung cancer is confirmed, genetic testing can be done on the lung tissue to identify details about the cancer that can help inform treatment.

Further details related to country-based variations in diagnosis are provided in the report…

Metastatic Non-small Cell Lung Cancer Epidemiology

The Metastatic Non-small Cell Lung Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Non-small Cell Lung Cancer, total incident cases of Non-small Cell Lung Cancer by histology, total cases of Non-small Cell Lung Cancer by stages, total incident cases of Non-small Cell Lung Cancer by genetic mutation/biomarkers, total treated cases of Non-small Cell Lung Cancer by line of therapies in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In the US, in 2022, there were approximately 200,000 new cases of lung cancer (~113,000 in men and ~88,000 in women). About 10-15% of all lung cancers are SCLC, and about 80-85% are Non-Small Cell Lung Cancer.
• The three main histological subtypes of Non-Small Cell Lung Cancer are Adenocarcinoma, Squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the United States, approximately 57% of all lung cancers are adenocarcinomas. About 25-30% of all lung cancers are Squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 2% of all lung cancers.
• Among the age-specific contribution, age =65 years are affected more by NSCLC than age <65 years. In 2019, there were 132,764 cases of NSCLC in age =65 years in the United States.
• In the US, in 2022, there were approximately 110,000 metastatic cases of NSCLC (De novo advanced/metastatic patients and recurrent patients from early stages).
• The two main subtypes of KRAS Non-Small Cell Lung Cancer are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~22,000 cases comprised of KRAS G12C, and ~38,000 cases comprised of KRAS non-G12C in 2022.

Scope of the Report:

• The report covers a segment of executive summary, and a descriptive overview of metastatic non-small cell lung cancer, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of the metastatic non-small cell lung cancer epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Metastatic Non-Small Cell Lung Cancer Report Insights

• Patient Population
• Patient population by stage and age
• Country-wise Epidemiology Distribution

Metastatic Non-Small Cell Lung Cancer Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Metastatic Non-small Cell Lung Cancer Epidemiology Segmentation

Metastatic Non-Small Cell Lung Cancer Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs:

• What are the disease risks and burdens of metastatic non-small cell lung cancer? What will be the growth opportunities across the 7MM concerning the patient population with metastatic non-small cell lung cancer?
• What is the historical and forecasted non-small cell lung cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which age group is the largest contributor in patients affected with metastatic non-small cell lung cancer?
• Which biomarker has the highest patient share in metastatic non-small cell lung cancer?

Reasons to buy:

• Insights on patient disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.